December 25, 2017
Otsuka Pharmaceutical Co., Ltd.
Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and DKSH Myanmar Ltd., a subsidiary of DKSH Myanmar Co., Ltd. (DKSH), have entered into an agreement in which the two companies are to market Otsuka's cardiovascular gastroenterology prescription drugs in the Republic of the Union of Myanmar. Through DKSH, sales and distribution of the products began in December 2017.
Both companies have deep experience in South East Asia - Otsuka has had a presence there since 1974 and DKSH has been present in the region since 1865.
In the rapidly expanding South East Asian region, Myanmar's nominal Gross Domestic Product (GDP) is projected to increase from USD 63 billion in 2014 to over USD 91 billion by 2020*1. Under Myanmar Health Vision 2030, a long-term health development plan was formulated to prepare for future medical challenges, while the country's pharmaceutical imports are expected to expand in size from USD 371 million in 2016 to USD 563 million*2 by 2021.
Through this alliance, the two companies will create a joint marketing team to promote and distribute Otsuka's products, in Myanmar. By supplying Otsuka's innovative medicines to Myanmar, the two companies aim to contribute to patient wellbeing and maximize product value.
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: "Otsuka-people creating new products for better health worldwide." Otsuka focuses on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue.
Otsuka Pharmaceutical is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately USD 11 billion in 2016.
Learn more at https://www.otsuka.co.jp/en.
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 780 business locations in 36 countries - 750 of them in Asia - and 30,320 specialized staff, DKSH generated net sales of CHF 10.5 billion in 2016. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.
DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, capillary physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With 120 business locations in 13 countries and around 9,740 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of CHF 5.5 billion in 2016.
- 1World Economic Outlook Database, IMF, published in October 2017
- 2Myanmar Pharmaceuticals & Healthcare Report, Q3 2017, BMI Research, data taken from UN Comtrade.
Information in this news release was current as of the original release date.